A study makes a case for targeting colorectal cancer screening in older adults so that those who will benefit do get tested, and those who won’t benefit aren’t exposed to unnecessary burdens.
Overall, cancer incidence rates fell approximately 1% annually and overall death rates decreased by an average of 1.6% annually between 2003 and 2007.
Nephron-sparing surgery now appears to benefit long-term kidney function in cases involving renal tumors larger than 4 cm—even in elderly patients.
Racial and sex disparities exist in cancer-related pain rates, according to a survey of diverse cancer survivors by Carmen R. Green, MD, of the University of Michigan, and colleagues.
If the US population ages at the rate predicted by the US Census Bureau and cancer incidence, survival rates, and costs remain stable, in the year 2020 direct cancer care expenditures will reach $157.77 billion in 2010 dollars.
Sending patients reminders to undergo colorectal cancer screening can increase screening rates in the short term, according to two recent reports.
Injectable dolasetron mesylate (Anzemet) should no longer be used to prevent chemotherapy-related nausea and vomiting in cancer patients of all ages, the FDA is warning health professionals.
The risk of developing cancer from computed tomography (CT) scans appears to be significantly lower than previous estimates of 1.5% to 2% in the general population, conclude researchers.
